| 摘要 |
The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethylpropionyl)-(5R)-5-[(2-ethylaminoethanesulfonylamino)methyl]-5-phenyl-4,5-dihydro[1,3,4]thiadiazol-2-yl}-2,2-dimethylpropionamide that minimize undesirable chiral conversion to the less active S enantiomeric form. |
